Data di Pubblicazione:
2012
Abstract:
Purpose: To evaluate the prognostic value of FDG-PET/CT after neo-adjuvant
therapy in locally advanced oesophageal cancer (EC) patients.
Methods and Materials: Among 108 EC patients who underwent FDG-PET/
CT after neo-adjuvant treatment, we selected 56 patients without evidence or
suspicious for distant metastases. All patients were followed for a mean period of
13±9 months from nuclear imaging. PET/CT findings were correlated with patient
management and long-term prognosis. Chi-square test was used for comparison
of categorical variables and t-Student test for continuous data. Survival curves
were computed using Kaplan Meier method. A p value of < 0.05 was considered
statistically significant.
Results: 15 patients had negative and 41 positive (27 vs. 73%) PET/CT after
neo-adjuvant therapy. 6/15 patients underwent radical-intent surgery and 9/15
did not, whereas 31/41 performed surgery and 10/41 did not (p < 0.05). After a
median time of 10 months, 28 patients were disease-free, 15 relapsed and 11 died.
The event-free survival was significantly higher in patients with negative than with
positive PET/CT after neo-adjuvant treatment (73 vs. 41%; log rank p < 0.05).
Considering patients with positive PET/CT, in non-surgery subset only 1 patient
was alive without evidence of disease while in surgery subset 17 patients were
disease-free (10 vs. 55%, p < 0.001).
Conclusion: PET/CT could stratify the recurrence risk of EC patients based on
treatment efficacy. After 13 months from PET/CT, 89% of patients with negative
PET/CT who did not undergo surgery resulted disease free. A positive PET/CT
after neo-adjuvant therapy should be followed by surgery for improving the eventfree
survival.
therapy in locally advanced oesophageal cancer (EC) patients.
Methods and Materials: Among 108 EC patients who underwent FDG-PET/
CT after neo-adjuvant treatment, we selected 56 patients without evidence or
suspicious for distant metastases. All patients were followed for a mean period of
13±9 months from nuclear imaging. PET/CT findings were correlated with patient
management and long-term prognosis. Chi-square test was used for comparison
of categorical variables and t-Student test for continuous data. Survival curves
were computed using Kaplan Meier method. A p value of < 0.05 was considered
statistically significant.
Results: 15 patients had negative and 41 positive (27 vs. 73%) PET/CT after
neo-adjuvant therapy. 6/15 patients underwent radical-intent surgery and 9/15
did not, whereas 31/41 performed surgery and 10/41 did not (p < 0.05). After a
median time of 10 months, 28 patients were disease-free, 15 relapsed and 11 died.
The event-free survival was significantly higher in patients with negative than with
positive PET/CT after neo-adjuvant treatment (73 vs. 41%; log rank p < 0.05).
Considering patients with positive PET/CT, in non-surgery subset only 1 patient
was alive without evidence of disease while in surgery subset 17 patients were
disease-free (10 vs. 55%, p < 0.001).
Conclusion: PET/CT could stratify the recurrence risk of EC patients based on
treatment efficacy. After 13 months from PET/CT, 89% of patients with negative
PET/CT who did not undergo surgery resulted disease free. A positive PET/CT
after neo-adjuvant therapy should be followed by surgery for improving the eventfree
survival.
Tipologia CRIS:
4.2 Abstract in Atti di convegno
Elenco autori:
Castoro, Carlo
Link alla scheda completa:
Titolo del libro:
Book of Abstracts
Pubblicato in: